Yingshibio and mosadong have reached a global clinical cooperation to jointly evaluate the combination of in10018 and pabolizumab

January 7, 2020 / AP / -- Yingshi Biotechnology (Shanghai) Co., Ltd (hereinafter referred to as "Yingshi biology" or "company"), a new biotechnological pioneer in clinical stage committed to the development of innovative and individualized drugs with global influence, announced that the company has recently worked with Merck, New Jersey (named Merck outside the United States and Canada) To reach a global clinical cooperation, the two sides will jointly assess the safety, pharmacokinetics and antitumor efficacy of the combination of in0018, a adhesion ban kinase (FAK) inhibitor of Yingshi biology, and pembrolizumab, the world's leading PD-1 tumor immunodrug, in the treatment of pancreatic cancer This is the first global clinical study in cooperation between the two sides The main originator of this research is the metazoan, which provides the mAb of pablizumab Dr Wang Zaiqi, founder and CEO of Yingshi biology, said: "changing the tumor microenvironment is one of the key elements to conquer cancer In 10018 is a FAK inhibitor with" best in class "potential, which can overcome the tumor matrix fibrosis barrier and have a significant impact on the tumor microenvironment We are very pleased that yingshibio and mosadon have reached an important global clinical cooperation, and look forward to the new breakthrough for the treatment of pancreatic cancer through the evaluation of the combination of in10018 and pabolizumab This cooperation marks another important step in the implementation of the strategy of "research and development of the best combination drugs" of Yingshi biology Dr Manuel Hidalgo Medina, director of Hematology and Oncology Department of wil Cornell Medical College and New York Presbyterian Hospital / wil Cornell Medical Center, and a world leading pancreatic cancer expert, said: "there is a huge unmet clinical demand in the field of pancreatic cancer treatment We need to attack tumor cells and tumor matrix at the same time to produce more effective treatment programs The combination of FAK inhibitors with other therapeutic paradigms is expected to be a rule changer in the treatment of pancreatic cancer "Tumor matrix is one of the key issues in the treatment of pancreatic cancer," commented Professor Paul Timpson, a leading expert in tumor matrix and drug resistance research, who published relevant research results in top academic journals such as naturecommunication "Our recent research shows that, in terms of mechanism, FAK inhibitors can significantly reduce the fibrosis of tumor matrix So that the therapeutic drugs can enter into the tumor and improve the sensitivity of pancreatic cancer patients to chemotherapy or immunotherapy As for in10018 in10018, the compound code was bi853520 It is an efficient and highly selective ATP competitive focal adhesion kinase (FAK) inhibitor It is currently in the clinical development stage in the United States and China It has the exclusive global development and commercial rights and interests in the compound The early clinical data of in10018 showed good safety and effectiveness for a variety of tumor types In addition to the effectiveness of single drug, in10018 is expected to overcome the fibrotic barrier of tumor matrix, improve the local immune function, so as to improve the efficacy of targeted treatment, chemotherapy and immunotherapy, and become a new choice of combination drugs for many existing treatment schemes About Yingshi biological Yingshi, founded at the end of 2018, is a new biotechnological cutting-edge in the clinical research and development stage With disease biology as the source of innovation, the company is committed to building an efficient engine for clinical transformation and concept verification, becoming a new drug R & D company based in China and having a global impact The company has completed rounds a financing of tens of millions of dollars, established a high-level R & D and clinical team across Shanghai, Beijing, the United States, Canada and Australia, built a R & D pipeline with global patent rights guided by "best combination drug R & D", and formed a partnership with many multinational drug enterprises including MSD, Roche and bringer Ingelheim Source: Yingshi biology 37